Cat. No.: HY-W008947

SEW2871

10 Cited Publications

고객리뷰

Based on 10 publication(s) in Google Scholar

SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.88%
CAS No.: 256414-75-2
화학식: C₂₀H₁₀F₆N₂OS
분자량:440.36

보관:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

SEW2871 Chemical Structure

CAS No.: 256414-75-2

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (10)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

S1PR1

13.8 nM (EC₅₀)

All LPL Receptor Isoforms :

All ERK Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	>10000 nM Compound: 10	Displacement of [33P]sphingosine 1 phosphate from human S1P3 receptor expressed in CHO cells Displacement of [33P]sphingosine 1 phosphate from human S1P3 receptor expressed in CHO cells	[PMID: 15615513]
CHO	IC₅₀	>10000 nM Compound: 10	Displacement of [33P]sphingosine 1 phosphate from human S1P4 receptor expressed in CHO cells Displacement of [33P]sphingosine 1 phosphate from human S1P4 receptor expressed in CHO cells	[PMID: 15615513]
CHO	IC₅₀	37 nM Compound: 10	Displacement of [33P]sphingosine 1 phosphate from human S1P1 receptor expressed in CHO cells Displacement of [33P]sphingosine 1 phosphate from human S1P1 receptor expressed in CHO cells	[PMID: 15615513]
CHO	IC₅₀	4600 nM Compound: 10	Displacement of [33P]sphingosine 1 phosphate from human S1P5 receptor expressed in CHO cells Displacement of [33P]sphingosine 1 phosphate from human S1P5 receptor expressed in CHO cells	[PMID: 15615513]
CHO	IC₅₀	>10000 nM Compound: 10	Displacement of [33P]sphingosine 1 phosphate from human S1P2 receptor expressed in CHO cells Displacement of [33P]sphingosine 1 phosphate from human S1P2 receptor expressed in CHO cells	[PMID: 15615513]
CHO	IC₅₀	>10 nM Compound: SEW-2871	Displacement of [33P]S1P from human S1P3R expressed in CHO cell membranes Displacement of [33P]S1P from human S1P3R expressed in CHO cell membranes	[PMID: 24900286]
CHO	IC₅₀	37 nM Compound: SEW-2871	Displacement of [33P]S1P from human S1P1R expressed in CHO cell membranes Displacement of [33P]S1P from human S1P1R expressed in CHO cell membranes	[PMID: 24900286]
CHO-K1	EC₅₀	>25 μM Compound: 3, SEW2871	Agonist activity at human S1P3 receptor expressed in CHO-K1 cells co-expressing Gq/i5 G-protein assessed as calcium mobilization by FLIPR assay Agonist activity at human S1P3 receptor expressed in CHO-K1 cells co-expressing Gq/i5 G-protein assessed as calcium mobilization by FLIPR assay	[PMID: 22104144]
U2OS	EC₅₀	0.27 μM Compound: 3, SEW2871	Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization into cytoplasm using Hoechst dye staining Agonist activity at human S1P1 receptor expressed in human U2OS cells co-expressing eGFP assessed as receptor internalization into cytoplasm using Hoechst dye staining	[PMID: 22104144]

In Vitro

SEW2871 exerts a powerful migratory effect by increasing smooth muscle α-actin, procollagen αI and αIII, and total hydroxyproline contents in LX-2 cells (a human hepatic stellate cell line)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SEW2871 (20 mg/kg, Gavage, once daily for 2 weeks) ameliorates established experimental colitis in IL-10^–/– mice^[3].
? SEW2871 (0.5 mg/kg, IP, daily for 2 weeks) inhibited β amyloid (Aβ_1-42)-induced spatial memory impairment and hippocampal neuronal loss in a rat model of Alzheimer’s disease^[2].
? SEW2871 (0-0.3 mg/kg, IV) attenuates LPS-induced acute inflammatory lung injury, produces dose-dependent alveolar and vascular barrier protection in C57Bl/6 mice^[2].
? SEW2871 is effective in protecting kidneys against ischaemia-reperfusion injury by reducing CD4⁺ T cell infiltration in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

IL-10^–/– (interleukin (IL)-10 gene-deficient) mice, a murine model of Crohn's disease (CD)^[3]
Dosage:

20 mg/kg
Administration:

Gavage, once daily for 2 weeks
Result:

Ameliorated established colitis in IL-10^–/– mice, associated with a reduction of serum amyloid A concentration, a decreased colon MPO concentration, a depletion of the peripheral CD4⁺CD45⁺ T cells and a reduction of the homing of T cells into colon LP. Suppressed typical cytokines of T helper type 1 (Th1) and Th17 cells and p-STAT-3 expression, and significantly decreased TNF-α, IFN-γ, IL-1β and IL-17A mRNA levels.

Chemical Information

CAS No. 256414-75-2
Appearance Solid
분자량 440.36
화학식 C₂₀H₁₀F₆N₂OS
Color White to light yellow
SMILES

FC(C1=CC(C2=NOC(C3=CC(C4=CC=CC=C4)=C(C(F)(F)F)S3)=N2)=CC=C1)(F)F
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (10)

All

Sort by:

Journal Impact Factor

Nat Commun

Astrocyte-derived clusterin disrupts glial physiology to obstruct remyelination in mouse models of demyelinating diseases. [Abstract]

2024 Sep 6;15(1):7791. PMID: 39242637
Adv Sci (Weinh)

Diabetes Mellitus Facilitates Gallstone Formation Through CXCR2-NETs-Mediated Liver-Bile Barrier Damage. [Abstract]

2026 Apr;13(24):e19500. PMID: 41698066
J Renin Angiotensin Aldosterone Syst

2025 Oct 16.
Neurosci Bull

Alpha-synuclein Fibrils Inhibit Activation of the BDNF/ERK Signaling Loop in the mPFC to Induce Parkinson's Disease-like Alterations with Depression. [Abstract]

2025 Jun;41(6):951-969. PMID: 39609371
Am J Physiol Cell Physiol

Glycolytic enzyme PFKFB3 regulates sphingosinae 1-phosphate receptor 1 in proangiogenic glomerular endothelial cells under diabetic condition. [Abstract]

2023 Nov 1;325(5):C1354-C1368. PMID: 37781737
iScience

Broad and diverse roles of sphingosine-1-phosphate/sphingosine-1-phosphate receptors in the prostate. [Abstract]

2024 Oct 30;27(12):111290. PMID: 39618500
Naunyn Schmiedebergs Arch Pharmacol

Label-free cell phenotypic profiling of sphingosine-1-phosphate receptor 1 and discovery of its agonist from natural products. [Abstract]

2026 May 29. PMID: 42209736
Reprod Biomed Online

Blocking sphingosine 1-phosphate receptor 1 with modulators reduces immune cells infiltration and alleviates endometriosis in mice. [Abstract]

2023 Nov;47(5):103304. PMID: 37757611
bioRxiv

Gz Enhanced Signal Transduction assaY (GZESTY) for GPCR deorphanization. [Abstract]

2024 Jul 26:2024.07.26.605282. PMID: 39091869
Research Square Preprint

2023 Dec 1.

용액&용해도

In Vitro:

DMF : 100 mg/mL (227.09 mM; Need ultrasonic)

DMSO : 25 mg/mL (56.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 20 mg/mL (45.42 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2709 mL

11.3543 mL

22.7087 mL

5 mM

0.4542 mL

2.2709 mL

4.5417 mL

10 mM

0.2271 mL

1.1354 mL

2.2709 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2 mg/mL (4.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Park SJ, et al. Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery. Biomol Ther (Seoul). 2017 Jan 1;25(1):80-90. [Content Brief]

[2]. Jo E, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol. 2005 Jun;12(6):703-15. [Content Brief]

[3]. Dong J, et al. Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice. Clin Exp Immunol. 2014 Jul;177(1):94-101. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO / DMF	1 mM	2.2709 mL	11.3543 mL	22.7087 mL	56.7717 mL
	5 mM	0.4542 mL	2.2709 mL	4.5417 mL	11.3543 mL
	10 mM	0.2271 mL	1.1354 mL	2.2709 mL	5.6772 mL
	15 mM	0.1514 mL	0.7570 mL	1.5139 mL	3.7848 mL
	20 mM	0.1135 mL	0.5677 mL	1.1354 mL	2.8386 mL
	25 mM	0.0908 mL	0.4542 mL	0.9083 mL	2.2709 mL
	30 mM	0.0757 mL	0.3785 mL	0.7570 mL	1.8924 mL
	40 mM	0.0568 mL	0.2839 mL	0.5677 mL	1.4193 mL
DMSO / DMF	50 mM	0.0454 mL	0.2271 mL	0.4542 mL	1.1354 mL
DMF	60 mM	0.0378 mL	0.1892 mL	0.3785 mL	0.9462 mL
	80 mM	0.0284 mL	0.1419 mL	0.2839 mL	0.7096 mL
	100 mM	0.0227 mL	0.1135 mL	0.2271 mL	0.5677 mL

Keywords

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

SEW​2871

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Human Metabolite Library

Osteogenesis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Activators Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) SEW​2871

All LPL Receptor Isoforms

All ERK Isoforms

All Akt Isoforms

Biological Activity

Chemical Information

Publications (10)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

SEW​2871 Related Classifications

HY-W008947 Related Classifications

SEW2871

Publications Citing Use of MedChemExpress (MCE) SEW2871

SEW2871 Related Classifications